Introduction
============

Breast cancer (BC) is one of the most common cancers in women worldwide. It is estimated that \>508,000 women succumbed to BC in 2011 ([@b1-ol-0-0-5351]). Although BC used to be a common disease in the developed world, recently \~50% of new cases and 58% of deaths have occurred in less developed countries ([@b1-ol-0-0-5351]). Localized BC at an early stage has an improved prognosis and requires less severe treatment with a survival rate of 98%. However, diagnosis after tumor metastasis significantly reduces the survival rate to 27% ([@b2-ol-0-0-5351]). Early detection may greatly improve the prognosis of patients with BC. Screening through mammography has shown a significant reduction of mortality through the early detection of disease ([@b3-ol-0-0-5351]). However, its sensitivity and specificity remain dissatisfactory ([@b2-ol-0-0-5351]). False-positive results are more common for younger women, women who have had previous breast biopsies, women with a family history of BC and women who are taking estrogen ([@b4-ol-0-0-5351],[@b5-ol-0-0-5351]). Molecular biomarkers are novel methods of indirect and direct detection of BC.

Epigenetic alteration is one of the most common molecular changes identified in the progression of human cancer ([@b6-ol-0-0-5351],[@b7-ol-0-0-5351]). Epigenetic mechanisms include aberrant DNA methylation, changes in histone and chromatin structure by post-translational modification of histone proteins and alterations in the expression of microRNAs ([@b8-ol-0-0-5351]). Aberrant DNA methylation may alter normal gene expression, genomic structure and genetic stability ([@b9-ol-0-0-5351]). It is well established that widespread changes of DNA methylation occur during carcinogenesis and tumor progression ([@b10-ol-0-0-5351]). Distinct from other biomarkers in BC which are typically based on gene expression, DNA methylation has been identified to have independent prognostic values that can be used in tailoring treatment to patients who are receiving uniform therapy regimens ([@b11-ol-0-0-5351]).

Promoter methylation predominantly follows a tumor-specific pattern and has been reported to be a useful biomarker in various types of cancer, including invasive BC ([@b12-ol-0-0-5351]). Previous studies have shown the frequent methylation of genes involved in cell cycle regulation \[cyclin dependent kinase inhibitor 2A (*P16*^INK4A^), ARF tumor suppressor, cyclin dependent kinase inhibitor 2B, cyclin D2 (*CCDN2*) and death associated protein kinase 1 (*DAPK*)\], DNA repair \[O-6-methylguanine-DNA methyltransferase (*MGMT*) and MutL homolog 1\], xenobiotic metabolism \[glutathione S-transferase pi 1 (*GSTP1*)\], signal transduction \[retinoic acid receptor beta 2 (*RAR*β*2*), WNT signaling pathway regulator (*APC*) and estrogen receptor 2 (*ER*β)\], adhesion and metastasis (cadherin 1 and cadherin 13) in BC ([@b13-ol-0-0-5351]--[@b16-ol-0-0-5351]). As these alterations occurred in cancer tissues at a higher frequency, they are potentially useful biomarkers for detecting cancer ([@b17-ol-0-0-5351]). Using promoter methylation of a panel of common cancer-related genes can discriminate normal and cancer tissues with a promising sensitivity and specificity ([@b18-ol-0-0-5351]). Since BC is heterogeneous, methylation status and the type of genes remain discordant among different studies ([@b18-ol-0-0-5351]). Therefore the true frequency and utility of DNA methylation as a biomarker in BC has yet to be established ([@b12-ol-0-0-5351]).

In order to search for a reliable gene panel for detecting BC, the present study qualitatively assessed the methylation frequency of seven candidate genes \[breast cancer 1, early onset; DNA repair associated (*BRCA1*), *GSTP1*, *P16*^INK4A^, *MGMT*, phosphatase and tensin homolog (*PTEN*), *RAR*β*2* and *CCND2*) and their protein expression in a Chinese population.

Materials and methods
=====================

### Ethical statement

The Institutional Review Board of Nanjing Medical University (Nanjing, China) approved the study. Written informed consent was obtained from all individual participants included in the study.

### Patients and specimens

A total of 70 female patients with BC (age range, 32--93 years; median age, 54.5 years) were recruited from the First People\'s Hospital of Zhenjiang City (Zhenjiang, China) between April 2012 and December 2014. Patients were diagnosed via pathological evidence. Tumor stage was determined according to the Classification of Malignant Tumors Staging System (TNM) ([@b19-ol-0-0-5351]). To investigate the diagnostic value of DNA methylation in BC, 20 patients with benign breast diseases (BBD; age range, 20--63 years; median, 40 years) were recruited as the controls. After obtaining written informed consent from all participants, trained interviewers conducted a questionnaire to collect patient\'s basic characteristics and clinical information. For patients who had undergone surgery, tissues in the center of the cancer lesion and remote normal appearing breast tissue were excised and stored at −80°C until the subsequent extraction of DNA. None of the enrolled patients had received preoperative chemotherapy or radiation therapy.

### DNA extraction and bisulfite modification

DNA was extracted from frozen tissue using a QIAamp DNA Mini kit (Qiagen Inc., Valencia, CA, USA) according to the manufacturer\'s instructions. Following quantification via NanoDrop 2000 (Thermo Fisher Scientific, Inc., Waltham, MA, USA), DNA samples were bisulphite converted and purified using the EpiTect Fast DNA Bisulfite kit (Qiagen, Inc.).

### Primer design and methylation detection

CpG island methylation at the promoter region of *BRCA1*, *GSTP1*, *P16INK4A*, *MGMT*, *PTEN*, *RARβ2* and *CCND2* was determined by methylation specific polymerase chain reaction (MSP) following sodium bisulfite modification of the DNA. Prior to the analysis of the methylation status of the target genes, the presence of bisulfite modified DNA in each sample was determined by amplification of 133-bp DNA fragment of the β-actin gene, which was used for quality control ([@b20-ol-0-0-5351]). Modified DNA was amplified in a total volume of 25 µl solution containing 0.8 U hot-start Taq polymerase (Takara, Japan), 10X PCR buffer (Mg^2+^ plus), 2.5 mM of each dNTP, 20 pmol of each primer and 80 ng of bisulfite-modified genomic DNA as templates. Cycling conditions consisted of an initial denaturation step at 95°C for 5 min, followed by 38 cycles of 30 sec at 95°C, 30 sec at the relevant annealing temperature ([Table I](#tI-ol-0-0-5351){ref-type="table"}) and 45 sec at 72°C. The reaction was terminated with a 10-min extension at 72°C. PCR products (7--8 µl) were resolved on a 2.5% agarose gel containing ethidium bromide and visualized under UV illumination. To avoid the occurrance of false positive and false negative results in the reactions, each set of PCR contained positive and negative controls. Peripheral blood lymphocyte DNA treated *in vitro* with SssI methyltransferase (New England Biolabs, Inc., Beverly, MA, USA) was used as a positive control of methylated DNA. DNA from normal lymphocytes was used as a control of unmethylated alleles. PCR reagent without DNA template was used as a blank control. The primers were designed by Nanjing Steed BioTechnologies Co., Ltd. (Nanjing, China) ([@b21-ol-0-0-5351]--[@b27-ol-0-0-5351]).

### Immunohistochemical analysis

Immunohistochemical analysis was used to evaluate the expression of specific genes in the breast tissues. Cut from the paraffin-embedded blocks using a microtome, 4-µm-thick sections were transferred to gelatin coated slides, and dried at 56°C for 1 h. Paraffin sections on slides were dewaxed in xylene twice for 15 min and rehydrated in a grade series of alcohol (100, 100, 90, 80 and 70%). Slides were subsequently placed in a glass jar filled with citrate buffer (0.01 M; pH 6.0) in a microwave oven for antigen retrieval and heated for 10 min at 97°C. Following cooling in the jar at room temperature, the sections were treated with 3% H~2~O~2~ for 20 min to quench the endogenous peroxidase activity. Non-specific binding was blocked with 10% goat serum (ZSJB-BIO, Beijing, China) in phosphate-buffered saline (PBS; 0.01 M; pH 7.4) for 30 min at room temperature. Without rinsing, the slides were incubated with primary antibodies against *BRCA1* (MS110; ab16780; diluted 1:300 in PBS; Abcam, Cambridge, UK) and *GSTP1* (3F2) (mouse monoclonal; \#3369; diluted 1:800 in PBS; Cell Signaling Technology, Inc., Danvers, MA, USA) overnight at 4°C. For negative controls, the primary antibody was replaced by PBS. Slides were washed with PBS, followed by incubation with the horseradish peroxidase-conjugated secondary antibody (Polink-2 plus Polymer HRP Detection System; PV-9002; ZSJB-BIO) for 30 min at room temperature in a moist chamber. The chromogenic reaction was visualized by diaminobenzidine and counterstained with hematoxylin. Finally, cells were gradually dehydrated with graded ethanol and sealed with neutral gum. Images were captured using an upright fluorescence microscope (Eclipse 80i; Nikon Corporation, Tokyo, Japan).

Immunohistochemical results were scored independently by two pathologists who were blind to the methylation status of the samples. The expression of *BRCA1* and *GSTP1* was evaluated using the semi-quantitative scoring criteria according to the staining intensity (0, negative; 1, weak; 2, moderate; and 3, strong) and the proportion of positive cells (0, positive in ≤5%; 1, positive in \>5 and ≤25%; 2, positive in \>25 and ≤50%; 3, positive in \>50 and ≤80%; and 4, positive in \>80% tumor cells). The two scores were multiplied together for each case and gene expression was subsequently graded as: 0, negative score; 1--4, weak expression score; 5--8, moderate expression score; and 9--12, strong expression score ([@b28-ol-0-0-5351]).

### Statistical analysis

Pearson\'s χ^2^ or Fisher\'s exact test were used to compare clinicopathological features between cases and controls. Mann-Whitney U testing was used for nonparametric distributed variables. Discriminant validity of selected genes was examined using the receiver operating characteristic (ROC) curve. Sensitivity, specificity, and the area under the curve (AUC) were calculated. P\<0.05 was considered to indicate a statistically significant difference. All statistical analyses were performed using SPSS 18.0 (SPSS, Inc., Chicago, IL, USA) or STATA 12.0 (Stata Corporation, College Station, TX, USA).

Results
=======

### Promoter methylation in BC and BBD

A total of 70 patients with BC (age range, 32--93 years; median age, 54.5 years) and 20 patients with BBD (age range, 20--63 years; median, 40 years) were enrolled. The majority of patients with BC were diagnosed with invasive ductal carcinoma (82.9%) and 55.7% were defined as stage II. For BBD patients, the majority were diagnosed with fibroadenoma (75.0%). Promoter methylation of *BRCA1*, *GSTP1*, *P16*^INK4A^, *MGMT*, *PTEN*, *RARβ2* and *CCND2* were measured. The frequency of hypermethylation in cancer tissues was 24.3, 31.4, 40.0, 27.1, 48.6, 55.7 and 67.1%, respectively, whereas the frequency of hypermethylation in BBD tissues was 0.0, 0.0, 20.0, 25.0, 40.0, 40.0 and 45.0%, respectively. There were 8 (11.4%) cases of hypermethylation in one gene, 17 (24.3%) cases of hypermethylation in two genes, 14 (20.0%) cases of hypermethylation in three genes, 17 (24.3%) cases of hypermethylation in four genes, 6 (8.6%) cases of hypermethylation in five genes, and 4 (5.7%) cases of hypermethylation in six genes. Only four patients did not exhibit any hypermethylation in these seven genes. *BRCA1* (24.3% in BC vs. 0.0% in BBD; P=0.034) and *GSTP1* (31.4% in BC vs. 0.0% in BBD; P=0.010) were significantly hypermethylated in BC as compared with BBD controls ([Table II](#tII-ol-0-0-5351){ref-type="table"}). [Fig. 1](#f1-ol-0-0-5351){ref-type="fig"} summarizes the methylation patterns of selected genes.

The sensitivity and specificity of each gene in distinguishing BC was calculated ([Table III](#tIII-ol-0-0-5351){ref-type="table"}). The AUC for selected genes ranged from 0.511 to 0.657. The sensitivity of each gene ranged from 24.3 to 67.1% and the specificity ranged from 55.0 to 100.0%. Methylation was scored as 1 and unmethylation as 0. The scores of the selected genes of the biomarker were totalled. When the combination of *BRCA1* and *GSTP1* was used, the AUC was 0.721 \[95% confidence interval (CI), 0.616--0.827; P=0.003\], with a sensitivity of 44.3% and a specificity of 100.0% at the cut-off point of 1, which indicated hypermethylation in at least one gene ([Table IV](#tIV-ol-0-0-5351){ref-type="table"}). When all seven candidate genes were used, the AUC was 0.741 (95% CI, 0.631--0.850; P=0.001), with a sensitivity of 58.6% and a specificity of 80.0% when the cut-off point was set at 3, which indicated hypermethylation in at least three genes ([Table V](#tV-ol-0-0-5351){ref-type="table"}). [Fig. 2](#f2-ol-0-0-5351){ref-type="fig"} illustrates the ROC curves of different combinations.

### Association of methylation status and clinicopathological parameters

[Table VI](#tVI-ol-0-0-5351){ref-type="table"} presents the methylation status of patients included in the present study stratified by age, tumor size, histologic type, clinical stage, lymph node metastases, menopausal status and the expression levels of estrogen receptor (*ER*), progesterone receptor (*PR*), human epidermal growth factor receptor 2 (*HER2*) and *P53* in cancerous tissues. Hypermethylation of *BRCA1* was demonstrated to be significantly more frequent in patients with lymph node metastasis (P=0.025). Hypermethylation of *P16*^INK4A^ was significantly associated with age (P=0.015), menopausal status (P=0.003) and *P53* expression (P=0.011). Hypermethylation of *PTEN* was significantly associated with menopausal status (P=0.027). *RARβ2* hypermethylation was significantly more common in *ER*-negative (P=0.002), *PR*-negative (P\<0.001) and *P53*-positive tumors (P=0.020).

### Association between gene methylation and protein expression

Immunohistochemical analysis was performed to assess the expression of *BRCA1* and *GSTP1*. With the increase of methylation frequency, protein expression decreased significantly (P\<0.05; [Table VII](#tVII-ol-0-0-5351){ref-type="table"}). Immunohistochemical staining results together with the promoter methylation status of *BRCA1* and *GSTP1* are shown in [Fig. 3](#f3-ol-0-0-5351){ref-type="fig"}.

Discussion
==========

Tumor biomarker tests are critical to the implementation of personalized medicine for patients at risk for or affected by BC. Newly developed genome-wide methods have revealed multiple epigenetic alterations that contribute to the carcinogenesis of BC ([@b29-ol-0-0-5351]). In the present study, seven cancer-related genes were selected and their methylation status was compared between 70 patients with sporadic BC and 20 controls with BBD. The methylation frequencies of these candidate genes were consistent with previous published articles ([@b14-ol-0-0-5351],[@b23-ol-0-0-5351],[@b30-ol-0-0-5351]--[@b33-ol-0-0-5351]). As expected, hypermethylation of these cancer-related genes was more frequent in cancer tissues as compared with BBD. Moreover, immunohistochemical analysis demonstrated that a significant reduction of gene expression is related to promoter methylation.

*BRCA1*, which is a typical tumor suppressor gene, contributes to the regulation of transcriptional activation, DNA repair, apoptosis, cell-cycle checkpoint control and chromosomal remodeling ([@b28-ol-0-0-5351]). A previous meta-analysis has provided evidence that *BRCA1* methylation is associated with the poor survival of patients with BC ([@b34-ol-0-0-5351]). The present study reported that hypermethylation of the *BRCA1* gene promoter was present in 24.3% of patients with BC, which was significantly associated with distant metastasis. This result led us to hypothesize that hypermethylation of the *BRCA1* gene promoter seemed to confer an advantage for tumors cells invasion, and may be used as a biomarker of advanced BC. The present study results demonstrated that *BRCA1* expression was significantly decreased in patients with *BRCA1* hypermethylation, which was consistent with the results reported by Shilpa *et al* ([@b35-ol-0-0-5351]). No methylation of *BRCA1* gene was detected in BBD patients.

*GSTP1*, which has an important role in the detoxification of toxic substances, is a phase II metabolic enzyme. The silencing of phase II metabolic enzymes by promoter methylation has been suggested to be implicated in the pathogenesis of BC ([@b36-ol-0-0-5351]). In the present study, the frequency of *GSTP1* methylation in BBD tissues was 0%. *GSTP1* protein expression was found to be absent or markedly decreased in the majority of the *GSTP1* methylated tumors, suggesting that epigenetic gene silencing in these tumors may interfere directly with the binding of sequence-specific transcription factors that would otherwise promote gene expression ([@b37-ol-0-0-5351]).

*P16*^INK4A^ is a major target in human carcinogenesis. It is epigenetically silenced in various human tumors and the downregulation of *P16*^INK4A^ protein has been reported in multiple cancers ([@b38-ol-0-0-5351]). In the present study, *P16*^INK4A^ hypermethylation was found to be associated with patient\'s age at the diagnosis and menopausal status. This suggested that loss of *P16*^INK4A^ expression through aberrant promoter methylation may occur more frequently in old women with BC ([@b39-ol-0-0-5351]). Moreover, it was observed that *P53* expression was associated with *P16*^INK4A^ methylation status. A previous study has revealed that *P16*^INK4A^ gene activity inversely modulated *p53* status and function in primary human mammary epithelial cells ([@b40-ol-0-0-5351]). Reduced levels of *P16*^INK4A^ protein stabilize *P53* protein through the inhibition of proteolytic degradation ([@b40-ol-0-0-5351]). Inactivation of *P16*^INK4A^/retinoblastoma and *P53/P21* pathways via hypermethylation has been linked to critical telomere shortening, leading to genome instability and ultimately to BC formation ([@b41-ol-0-0-5351]). This may partly explain the association between *P16*^INK4A^ methylation and *P53* expression.

*MGMT* catalyzes the transfer of the methyl group from O6-methylguanine to a cysteine residue of its active site ([@b42-ol-0-0-5351]). Tumors with low levels of protein expression due to the epigenetic silencing of *MGMT* in the promoter region have previously been examined ([@b42-ol-0-0-5351]). Consistent with the present findings, earlier studies have reported the frequency of *MGMT* methylation ranging from 22 to 32% ([@b43-ol-0-0-5351]).

*CCND2* belongs to a family of D-type cyclins ([@b44-ol-0-0-5351]). Previous studies revealed that high methylation levels of *CCND2* caused deregulation of the G1/S checkpoint, and affected clinicopathologic features of tumor aggressiveness in BC ([@b44-ol-0-0-5351]). A study by Pu *et al* ([@b45-ol-0-0-5351]) reported that methylation of *CCND2* (71%) was higher in invasive BCs, which was consistent with the findings of the present study.

*PTEN* was the first recognized tumor suppressor with lipid phosphatase activity ([@b46-ol-0-0-5351]). Zhang *et al* ([@b46-ol-0-0-5351]) reported that *PTEN* hypermethylation was detected in 31.1% of BC cases, which was lower than the present results (48.6%). Notably, the present study also found that *PTEN* methylation was more frequent in postmenopausal patients.

Retinoic acid, which has three subtypes (α, β and γ), induces growth inhibition and apoptosis by regulating gene expression through its nuclear receptors ([@b47-ol-0-0-5351]). The human *RAR*β gene has four isoforms (β1, β2, β3 and β4), with the β2 isoform being the most abundant. The protein encoded by *RAR*β*2* functions in the inhibition of proliferation, apoptosis and senescence ([@b48-ol-0-0-5351]). Lee *et al* ([@b49-ol-0-0-5351]) demonstrated that *RAR*β*2* and the *P53* tumor suppressor gene inhibited oncogene-induced focus formation. Expression of *HER2*, *ER* and *PR* proteins are considered to be predictive markers for hormone therapy response in BC ([@b20-ol-0-0-5351]). The present study found that *RAR*β*2* was more frequently hypermethylated in *ER*-negative, *PR*-negative and *P53* positive cancer patients, suggesting an interlink between cancer-related genes.

Studies testing the ability of promoter methylation profiles to distinguish benign and malignant diseases have yielded conflicting results ([@b17-ol-0-0-5351]). A study that included women with invasive BC, *in situ* BC and benign breast disease compared with healthy controls found that promoter methylation of three genes (*APC*, Ras association domain family 1 isoform A and *DAPK*) was detectable in DNA obtained from *in situ* lesions and invasive samples at all tumor stages ([@b50-ol-0-0-5351]). However, in another study, researchers found that fibroadenomas had patterns of methylation that were similar to those seen in BC cases ([@b51-ol-0-0-5351]). In the present study, hypermethylation was observed in some specific genes in patients with BBD, which was lower than that in BC cases, with a significantly different methylation rate in the genes of *BRCA1* and *GSTP1*. When *BRCA1* and *GSTP1* were combined, the specificity of diagnosing BC reached 100.0%; however, the sensitivity was only 44.3%. To achieve a more reliable gene panel, sensitivity and specificity were expected be enhanced by the addition of other genes that are frequently hypermethylated in BCs to the panel and a larger population.

The present study has some limitations. Firstly, the study protocol only focused on the aberrant DNA methylation of candidate genes. Other epigenetic traits, such as histone post-transcriptional modifications and non-coding RNAs, and genetic mutations are also critical for the spatio-temporal regulation of gene expression ([@b52-ol-0-0-5351],[@b53-ol-0-0-5351]). This may limit the diagnostic accuracy of biomarkers detected in this study. Secondly, due to the limitation of the MSP technology, only a few of CpG islands in the promoter region of genes were measured. The frequency of hypermethylation detected using MSP cannot fully reflect the methylation status of this gene. Therefore, to acquire a comprehensive understanding of DNA methylation status, more accurate and quantitative methods are required.

Promoter hypermethylation of *BRCA1, GSTP1, P16^INK4A^, MGMT, PTEN, RARβ2* and *CCND2* was frequently observed in BC and associated with various clinical pathological features. Hypermethylation of *BRCA1* and *GSTP1* was more common in cancerous tissues, which indicates these may be used as promising biomarkers for the diagnosis of BC.
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![Representative results of methylation-specific polymerase chain reaction analyses. Peripheral blood lymphocytes DNA treated by SssI methyltransferase was used as the methylation-positive control and DNA from normal lymphocytes was used as the unmethylation-positive control. NEG, negative control; Lane L1-L2, breast cancer samples; M, methylation; U, unmethylation; POS, positive control; *BRCA1*, breast cancer 1, early onset; DNA repair associated; *GSTP1*, glutathione S-transferase pi 1; *P16^INK4A^*, cyclin dependent kinase inhibitor 2A; *MGMT*, O-6-methylguanine-DNA methyltransferase; *PTEN*, phosphatase and tensin homolog; *RARβ2*, retinoic acid receptor beta 2; *CCND2*, cyclin D2.](ol-12-06-5145-g00){#f1-ol-0-0-5351}

![ROC analysis of DNA methylation. (A) ROC curve for the combination of seven candidate genes; (B) ROC curve for the combination of breast cancer 1, early onset; DNA repair associated and glutathione S-transferase pi 1. ROC, receiver operating characteristic.](ol-12-06-5145-g01){#f2-ol-0-0-5351}

![Immunohistochemical staining of *BRCA1* and *GSTP1*. (A) *BRCA1* negative; (B) tumor exhibiting weak staining; (C) tumor exhibiting moderate staining; (D) tumor exhibiting strong staining; (E) *GSTP1* negative; (F) tumor exhibiting weak staining; (G) tumor exhibiting moderate staining; and (H) tumor exhibiting strong staining (magnification, ×200). *BRCA1*, breast cancer 1, early onset; DNA repair associated; *GSTP1*, glutathione S-transferase pi 1.](ol-12-06-5145-g02){#f3-ol-0-0-5351}

###### 

Summary of primer sequences, chromosomal locations, annealing temperatures and product sizes used for methylation-specific polymerase chain reaction analyses.

  Genes          M/U   Sequence (5′-3′)                   Annealing (°C)   Product size (bp)   Ref
  -------------- ----- ---------------------------------- ---------------- ------------------- --------------------
  β-*actin*      --    F: TGGTGATGGAGGAGGTTTAGTAAGT       60.0             133                 [@b20-ol-0-0-5351]
                 --    R: AACCAATAAAACCTACTCCTCCCTTAA                                          
  *BRCA1*        M     F: GGTTAATTTAGAGTTTCGAGAGACG       65.0             182                 [@b21-ol-0-0-5351]
                       R: TCAACGAACTCACGCCGCGCAATCG                                            
                 U     F: GGTTAATTTAGAGTTTTGAGAGATG       62.0             182                 
                       R: TCAACAAACTCACACCACACAATCA                                            
  *GSTP1*        M     F: TTCGGGGTGTAGCGGTCGTC            55.0               91                [@b22-ol-0-0-5351]
                       R: GCCCCAATACTAAATCACGACG                                               
                 U     F: GATGTTTGGGGTGTAGTGGTTGTT        55.0               97                
                       R: CCACCCCAATACTAAATCACAACA                                             
  *P16^INK4A^*   M     F: TTATTAGAGGGTGGGGCGGATCGC        62.0             150                 [@b23-ol-0-0-5351]
                       R: GACCCCGAACCGCGACCGTAA                                                
                 U     F: TTATTAGAGGGTGGGGTGGATTGT        60.0             151                 
                       R: CAACCCCAAACCACAACCATAA                                               
  *MGMT*         M     F: TTTCGACGTTCGTAGGTTTTCGC         62.0               81                [@b24-ol-0-0-5351]
                       R: GCACTCTTCCGAAAACGAAACG                                               
                 U     F: TTTGTGTTTTGATGTTTGTAGGTTTTTGT   62.0               93                
                       R: AACTCCACACTCTTCCAAAAACAAAACA                                         
  *PTEN*         M     F: TTCGTTCGTCGTCGTCGTATTT          62.0             207                 [@b25-ol-0-0-5351]
                       R: GCCGCTTAACTCTAAACCGCAACCG                                            
                 U     F: GTGTTGGTGGAGGTAGTTGTTT          62.0             163                 
                       R: ACCACTTAACTCTAAACCACAACCA                                            
  *RARβ2*        M     F: TCGAGAACGCGAGCGATTCG            62.0             146                 [@b26-ol-0-0-5351]
                       R: GACCAATCCAACCGAAACGA                                                 
                 U     F: TTGAGAATGTGAGTGATTTGA           60.5             146                 
                       R: AACCAATCCAACCAAAACAA                                                 
  *CCND2*        M     F: TCGGTGTGGTTACGTTTAGC            59.0             160                 [@b27-ol-0-0-5351]
                       R: TAAAACGACGCGATACAACG                                                 
                 U     F: TGGTGTGGTTATGTTTAGTG            59.0             150                 
                       R: ACAATACAACATCTAAAACCAC                                               

M, methylated primer; U, unmethylated primer; F, forward primer; R, reverse primer; *BRCA1*, breast cancer 1, early onset; DNA repair associated; *GSTP1*, glutathione S-transferase pi 1; *P16^INK4A^*, cyclin dependent kinase inhibitor 2A; *MGMT*, O-6-methylguanine-DNA methyltransferase; *PTEN*, phosphatase and tensin homolog; *RARβ2*, retinoic acid receptor beta 2; *CCND2*, cyclin D2.

###### 

Methylation status of patients with BC and BBD.

  Genes          MU   BC, n (%)   BBD, n (%)   P-value
  -------------- ---- ----------- ------------ ---------
  *BRCA1*        M    17 (24.3)   0 (0.0)      0.034
                 U    53 (75.7)   20 (100.0)   
  *GSTP1*        M    22 (31.4)   0 (0.0)      0.010
                 U    48 (68.6)   20 (100.0)   
  *P16^INK4A^*   M    28 (40.0)   4 (20.0)     0.099
                 U    42 (60.0)   16 (80.0)    
  *MGMT*         M    19 (27.1)   5 (25.0)     0.848
                 U    51 (72.9)   15 (75.0)    
  *PTEN*         M    34 (48.6)   8 (40.0)     0.498
                 U    36 (51.4)   12 (60.0)    
  *RARβ2*        M    39 (55.7)   8 (40.0)     0.215
                 U    31 (44.3)   12 (60.0)    
  *CCND2*        M    47 (67.1)   9 (45.0)     0.072
                 U    23 (32.9)   11 (55.0)    

M, methylated; U, unmethylated; BC, breast cancer; BBD, benign breast disease; *BRCA1*, breast cancer 1, early onset; DNA repair associated; *GSTP1*, glutathione S-transferase pi 1; *P16^INK4A^*, cyclin dependent kinase inhibitor 2A; *MGMT*, O-6-methylguanine-DNA methyltransferase; *PTEN*, phosphatase and tensin homolog; *RARβ2*, retinoic acid receptor beta 2; *CCND2*, cyclin D2.

###### 

Diagnostic performance of candidate genes.

  Gene           BC pos./total   BBD pos./total   Sensitivity (%)   Specificity (%)   AUC     95% CI         P-value
  -------------- --------------- ---------------- ----------------- ----------------- ------- -------------- ---------
  *BRCA1*        17/70           0/20             24.3              100.0             0.621   0.497--0.745   0.099
  *GSTP1*        22/70           0/20             31.4              100.0             0.657   0.540--0.775   0.033
  *P16^INK4A^*   28/70           4/20             40.0                80.0            0.600   0.465--0.735   0.174
  *MGMT*         19/70           5/20             27.1                75.0            0.511   0.367--0.654   0.884
  *PTEN*         34/70           8/20             48.6                60.0            0.543   0.400--0.686   0.560
  *RARβ2*        39/70           8/20             55.7                60.0            0.579   0.437--0.720   0.286
  *CCND2*        47/70           9/20             67.1                55.0            0.611   0.468--0.754   0.133

BC, breast cancer; BBD, benign breast disease; AUC, area under the curve; CI, confidence interval; pos., positive; *BRCA1*, breast cancer 1, early onset; DNA repair associated; *GSTP1*, glutathione S-transferase pi 1; *P16^INK4A^*, cyclin dependent kinase inhibitor 2A; *MGMT*, O-6-methylguanine-DNA methyltransferase; *PTEN*, phosphatase and tensin homolog; *RARβ2*, retinoic acid receptor beta 2; *CCND2*, cyclin D2.

###### 

Combination of *BRCA1* and *GSTP1* for the diagnosis of breast cancer.

  Cut-point   Sensitivity (%)   Specificity (%)   Correctly classified (%)   LR+    LR-
  ----------- ----------------- ----------------- -------------------------- ------ ------
  ≥0          100.0               0.0             77.8                       1.00   --
  ≥1            44.3            100.0             56.7                       --     0.56
  ≥2            11.4            100.0             31.1                       --     0.89
  \>2           0.0             100.0             22.2                       --     1.00

LR, likelihood ratio.

###### 

Combination of seven candidate genes for the diagnosis of breast cancer.

  Cut-point   Sensitivity (%)   Specificity (%)   Correctly classified (%)   LR+    LR-
  ----------- ----------------- ----------------- -------------------------- ------ ------
  ≥0          100.0                 0.0           77.8                       1.00   --
  ≥1            94.3              10.0            75.6                       1.05   0.57
  ≥2            82.9              45.0            74.4                       1.51   0.38
  ≥3            58.6              80.0            63.3                       2.93   0.52
  ≥4            38.6              95.0            51.1                       7.71   0.65
  ≥5            14.3            100.0             33.3                       --     0.86
  ≥6            5.7             100.0             26.7                       --     0.94
  \>6           0.0             100.0             22.2                       --     1.00

LR, likelihood ratio.

###### 

Correlation of DNA methylation and clinicopathological parameters.

                                      *BRCA1* (%)   *GSTP1* (%)   *P16^INK4A^* (%)   *MGMT* (%)   *PTEN* (%)   *RARβ2* (%)   *CCND2* (%)                                                                           
  ----------------------- ----------- ------------- ------------- ------------------ ------------ ------------ ------------- ------------- ----------- ----------- ----------- ----------- ----------- ----------- -----------
  Age (years)                                                                                                                                                                                                      
    \<55                  35 (50.0)   10 (28.6)     25 (71.4)     8 (22.9)           27 (77.1)    9 (25.7)     26 (74.3)     9 (25.7)      26 (74.3)   14 (40.0)   21 (60.0)   19 (54.3)   16 (45.7)   22 (62.9)   13 (37.1)
    ≥55                   35 (50.0)   7 (20.0)      28 (80.0)     14 (40.0)          21 (60.0)    19 (54.3)    16 (45.7)     10 (28.6)     25 (71.4)   20 (57.1)   15 (42.9)   20 (57.1)   15 (42.9)   25 (71.4)   10 (28.6)
    P-value                           0.403                       0.122                           0.015                      0.788                     0.151                   0.810                   0.445       
  Size of tumor                                                                                                                                                                                                    
    \<2 cm                18 (25.7)   5 (27.8)      13 (72.2)     6 (33.3)           12 (66.7)    8 (44.4)     10 (55.6)     6 (33.3)      12 (66.7)   9 (50.0)    9 (50.0)    9 (50.0)    9 (50.0)    13 (72.2)   5 (27.8)
    ≥2 cm                 52 (74.3)   12 (23.1)     40 (76.9)     16 (30.8)          36 (69.2)    20 (38.5)    32 (61.5)     13 (25.0)     39 (75.0)   25 (48.1)   27 (51.9)   30 (57.7)   22 (42.3)   34 (65.4)   18 (34.6)
    P-value                           0.935                       0.840                           0.655                      0.706                     0.888                   0.571                   0.594       
  Histologic type                                                                                                                                                                                                  
    DCIS                  5 (7.1)     2 (40.0)      3 (60.0)      2 (40.0)           3 (60.0)     4 (80.0)     1 (20.0)      2 (40.0)      3 (60.0)    4 (80.0)    1 (20.0)    3 (60.0)    2 (40.0)    3 (60.0)    2 (40.0)
    IDC                   58 (82.9)   15 (25.9)     43 (74.1)     19 (32.8)          39 (67.2)    21 (36.2)    37 (63.8)     17 (29.3)     41 (70.7)   26 (44.8)   32 (55.2)   33 (56.9)   25 (43.1)   39 (67.2)   19 (32.8)
    Others                7 (10.0)    0 (0.0)       7 (100.0)     1 (14.3)           6 (85.7)     3 (42.9)     4 (57.1)      0 (0.0)       7 (100.0)   4 (57.1)    3 (42.9)    3 (42.9)    4 (57.1)    5 (71.4)    2 (28.6)
    P-value                           0.202                       0.602                           0.151                      0.173                     0.289                   0.891                   1.00        
  Clinical stages                                                                                                                                                                                                  
    I                     13 (18.6)   3 (23.1)      10 (76.9)     4 (30.8)           9 (69.2)     5 (38.5)     8 (61.5)      4 (30.8)      9 (69.2)    7 (53.8)    6 (46.2)    6 (46.2)    7 (53.8)    9 (69.2)    4 (30.8)
    II                    39 (55.7)   10 (25.6)     29 (74.4)     11 (28.2)          28 (71.8)    13 (33.3)    26 (66.7)     8 (20.5)      31 (79.5)   18 (46.2)   21 (53.8)   23 (59.0)   16 (41.0)   25 (64.1)   14 (35.9)
    III                   18 (25.7)   4 (22.2)      14 (77.8)     7 (38.9)           11 (61.1)    10 (55.6)    8 (44.4)      7 (38.9)      11 (61.1)   9 (50.0)    9 (50.0)    10 (55.6)   8 (44.4)    13 (72.2)   5 (27.8)
    P-value                           0.955                       0.725                           0.279                      0.338                     0.882                   0.723                   0.817       
  Lymph node metastases                                                                                                                                                                                            
    No                    33 (47.1)   4 (12.1)      29 (87.9)     9 (27.3)           24 (72.7)    10 (30.3)    23 (69.7)     9 (27.3)      24 (72.7)   16 (48.5)   17 (51.5)   18 (54.5)   15 (45.5)   23 (69.7)   10 (30.3)
    Yes                   37 (52.9)   13 (35.1)     24 (64.9)     13 (35.1)          24 (64.9)    18 (48.6)    19 (51.4)     10 (27.0)     27 (73.0)   18 (48.6)   19 (51.4)   21 (56.8)   16 (43.2)   24 (64.9)   13 (35.1)
    P-value                           0.025                       0.479                           0.118                      0.982                     0.989                   0.853                   0.667       
  Menopausal status                                                                                                                                                                                                
    Premenopausal         30 (42.9)   10 (33.3)     20 (66.7)     7 (23.3)           23 (76.7)    6 (20.0)     24 (80.0)     6 (20.0)      24 (80.0)   10 (33.3)   20 (66.7)   15 (50.0)   15 (50.0)   20 (66.7)   10 (33.3)
    Postmenopausal        40 (57.1)   7 (17.5)      33 (82.5)     15 (37.5)          25 (62.5)    22 (55.0)    18 (45.0)     13 (32.5)     27 (67.5)   24 (60.0)   16 (40.0)   24 (60.0)   16 (40.0)   27 (67.5)   13 (32.5)
    P-value                           0.126                       0.206                           0.003                      0.244                     0.027                   0.405                   0.941       
  *ER*                                                                                                                                                                                                             
    Positive              45 (64.3)   12 (26.7)     33 (73.3)     11 (24.4)          34 (75.6)    16 (35.6)    29 (64.4)     12 (26.7)     33 (73.3)   20 (44.4)   25 (55.6)   19 (42.2)   26 (57.8)   31 (68.9)   14 (31.1)
    Negative              25 (35.7)   5 (20.0)      20 (80.0)     11 (44.0)          14 (56.0)    12 (48.0)    13 (52.0)     7 (28.0)      18 (72.0)   14 (56.0)   11 (44.0)   20 (80.0)   5 (20.0)    16 (64.0)   9 (36.0)
    P-value                           0.533                       0.091                           0.309                      0.904                     0.354                   0.002                   0.676       
  *PR*                                                                                                                                                                                                             
    Positive              40 (57.1)   10 (25.0)     30 (75.0)     10 (25.0)          30 (75.0)    14 (35.0)    26 (65.0)     10 (25.0)     30 (75.0)   18 (45.0)   22 (55.0)   14 (35.0)   26 (65.0)   29 (72.5)   11 (27.5)
    Negative              30 (42.9)   7 (23.3)      23 (76.7)     12 (40.0)          18 (60.0)    14 (46.7)    16 (53.3)     9 (30.0)      21 (70.0)   16 (53.3)   14 (46.7)   25 (83.3)   5 (16.7)    18 (60.0)   12 (40.0)
    P-value                           0.872                       0.181                           0.324                      0.642                     0.490                   \<0.001                 0.271       
  *HER2*                                                                                                                                                                                                           
    Positive              36 (51.4)   10 (27.8)     26 (72.2)     11 (30.6)          25 (69.4)    14 (38.9)    22 (61.1)     11 (30.6)     25 (69.4)   20 (55.6)   16 (44.4)   22 (61.1)   14 (38.9)   23 (63.9)   13 (36.1)
    Negative              34 (48.6)   7 (20.6)      27 (79.4)     11 (32.4)          23 (67.6)    14 (41.2)    20 (58.8)     8 (23.5)      26 (76.5)   14 (41.2)   20 (58.8)   17 (50.0)   17 (50.0)   24 (70.6)   10 (29.4)
    P-value                           0.483                       0.871                           0.845                      0.509                     0.229                   0.350                   0.551       
  TNBC                                                                                                                                                                                                             
    No                    12 (17.1)   2 (16.7)      10 (83.3)     6 (50.0)           6 (50.0)     4 (33.3)     8 (66.7)      2 (16.7)      10 (83.3)   7 (58.3)    5 (41.7)    9 (75.0)    3 (25.0)    10 (83.3)   2 (16.7)
    Yes                   58 (82.9)   15 (25.9)     43 (74.1)     16 (27.6)          42 (72.4)    24 (41.4)    34 (58.6)     17 (29.3)     41 (70.7)   27 (46.6)   31 (53.4)   30 (51.7)   28 (48.3)   37 (63.8)   21 (36.2)
    P-value                           0.759                       0.238                           0.846                      0.589                     0.457                   0.140                   0.330       
  *P53*                                                                                                                                                                                                            
    Positive              38 (54.3)   9 (23.7)      29 (76.3)     12 (31.6)          26 (68.4)    10 (26.3)    28 (73.7)     9 (23.7)      29 (76.3)   15 (39.5)   23 (60.5)   26 (68.4)   12 (31.6)   23 (60.5)   15 (39.5)
    Negative              32 (45.7)   8 (25.0)      24 (75.0)     10 (31.2)          22 (68.8)    18 (56.2)    14 (43.8)     10 (31.2)     22 (68.8)   19 (59.4)   13 (40.6)   13 (40.6)   19 (59.4)   24 (75.0)   8 (25.0)
    P-value                           0.898                       0.976                           0.011                      0.478                     0.097                   0.020                   0.199       

DCIS, ductal carcinoma *in situ*; IDC, invasive ductal carcinoma; TNBC, triple-negative breast cancer; M, methylated; U, unmethylated; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor 2; *BRCA1*, breast cancer 1, early onset; DNA repair associated; *GSTP1*, glutathione S-transferase pi 1; *P16^INK4A^*, cyclin dependent kinase inhibitor 2A; *MGMT*, O-6-methylguanine-DNA methyltransferase; *PTEN*, phosphatase and tensin homolog; *RARβ2*, retinoic acid receptor beta 2; *CCND2*, cyclin D2.

###### 

Association between methylation and protein expression.

                      *BRCA1*, n (%)   *GSTP1*, n (%)               
  ------------------- ---------------- ---------------- ----------- -----------
  Negative            0 (0.0)          0 (0.0)          9 (100.0)   0 (0.0)
  Weak                14 (70.0)        6 (30.0)         9 (64.3)    5 (35.7)
  Moderate            3 (30.0)         7 (70.0)         4 (50.0)    4 (50.0)
  Strong              0 (0.0)          2 (100.0)        0 (0.0)     1 (100.0)
  P-value for trend   0.011            0.008                        

M, methylated; U, unmethylated; *BRCA1*, breast cancer 1, early onset; DNA repair associated; *GSTP1*, glutathione S-transferase pi 1.
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